Otonomy reports phase 2b topline data for OTO-104 in Meniere's disease
Otonomy announced topline results from its Phase 2b trial evaluating OTO-104 in patients with unilateral Ménière's disease. The primary endpoint of the trial was reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period. May 21, 2015